Form 4: Voss Capital Increases Rein Therapeutics Stake

Voss Capital, a 10% owner and director, significantly expanded its beneficial ownership in Rein Therapeutics, Inc. through recent common stock purchases.

Summary

• Voss Capital, LP, along with affiliated entities Voss Value Master Fund, L.P., Voss Value-Oriented Special Situations Fund, L.P., Voss Advisors GP, LLC, and Travis W. Cocke, collectively increased their beneficial ownership in Rein Therapeutics, Inc. (RNTX).
• The reporting persons are identified as a Director and 10% Owner of Rein Therapeutics, Inc.
• Transactions occurred on October 24, 2025, October 27, 2025, and October 28, 2025.
• A total of 305,050 shares of common stock were acquired across these dates.
• Purchase prices ranged from $1.3300 to $1.4000 per share.
• Following these transactions, Voss Value Master Fund, L.P. beneficially owns 822,258 shares, and Voss Value-Oriented Special Situations Fund, L.P. beneficially owns 500,000 shares.

Sentiment

Score: 8

Explanation: The significant increase in beneficial ownership by a 10% owner and director group, Voss Capital and its affiliates, through multiple open market purchases, indicates strong insider confidence in Rein Therapeutics, Inc.'s future prospects and valuation. This is generally viewed as a very positive signal by the market.

Positives

• Significant insider buying by a 10% owner and director group, indicating strong confidence in Rein Therapeutics, Inc.'s future prospects.
• The acquisition of 305,050 common shares across multiple transactions suggests a deliberate and sustained investment strategy.
• Purchases were made at prices ranging from $1.3300 to $1.4000, demonstrating conviction at current market valuations.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Management Comments

• Travis W. Cocke, as the managing member of Voss Capital and Voss GP, signed the filing on behalf of the reporting persons.
• The reporting persons undertake to provide full information regarding shares purchased at each separate price within the stated ranges upon request.

Industry Context

Insider buying, especially by a significant shareholder and director, is often interpreted by the market as a positive signal, suggesting that those with intimate knowledge of the company believe its stock is undervalued or that positive developments are anticipated. This activity can attract investor attention to Rein Therapeutics, Inc.

Related Party Transactions

• The reported transactions are related party dealings, as they involve a 10% owner and director group (Voss Capital and its affiliates) purchasing shares of the issuer (Rein Therapeutics, Inc.).

Stakeholder Impact

• Shareholders may view the increased insider ownership as a positive indicator of management and significant investor confidence, potentially leading to increased investor interest and a positive impact on share price.
• Employees, customers, suppliers, and creditors are not directly impacted by this specific type of filing, though a positive market sentiment could indirectly benefit the company's overall stability and reputation.

Key Dates

Recommendation

The substantial insider buying by a 10% owner and director group, Voss Capital, signals strong conviction in Rein Therapeutics, Inc.'s value proposition and future performance. Such significant purchases by well-informed parties often precede positive developments or reflect a belief that the stock is currently undervalued, making it an attractive buying opportunity for investors.

Keywords

Rein Therapeutics, RNTX, Voss Capital, insider buying, beneficial ownership, stock purchase, Form 4, institutional investor, director, 10% owner